Treatment for chronic hepatitis B (CHB) has improved significantly in the last 10 years but despite those improvements 360 million people or 5 percent of the world’s population remain chronically infected by the Hepatitis B virus (HBV). That's according to Gaithersburg, Md-based Vaxin Inc, the company recently announced that it has initiated Phase 1 clinical stage trial to test a vaccine treatment for HepTcell, its' immunotherapeutic compound to treat people who are chronically infected with HBV.
The trial sites will be located in the United Kingdom, a total of seven centers aims to recruit 72 patients with affected by HBV. The trial will also be the standard randomized, double-blind, placebo-controlled dose-escalation study with preliminary results expected to be reported in the fourth quarter of 2014.
According to Vaxin CEO, Bill Enright, funding for pre-clinical and manufacturing developments was funding by Innovate UK which gave $3.1 million towards the project and $16 million from Vaxin investors.